Epsametostat
CAS 2202678-06-4
MF C31H36F3N7O3 MW611.7 g/mol
N-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-{(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl}indolizine-7-carboxamide
N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-[(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl]indolizine-7-carboxamide
histone N-methyltransferase inhibitor, antineoplastic, Shanghai Haihe Pharmaceutical, HH 2853, (R)-HH2853
Epsametostat is an investigational new drug that is being evaluated for the treatment of peripheral T-cell lymphoma. It is a EZH1/EZH2 inhibitor developed by Shanghai Haihe Pharmaceutical Research & Development Co., Ltd.[1][2][3]
PAT
- Pyrido five-element aromatic ring compound, preparation method therefor and use thereofPublication Number: EP-3524602-A1Priority Date: 2016-09-07
- Pyrido five-element aromatic ring compound, preparation method therefor and use thereofPublication Number: US-2019211010-A1Priority Date: 2016-09-07
- Pyrido five-element aromatic ring compound, preparation method therefor and use thereofPublication Number: WO-2018045971-A1Priority Date: 2016-09-07
- Pyrido five-element aromatic ring compound, preparation method therefor and use thereofPublication Number: US-10968215-B2Priority Date: 2016-09-07Grant Date: 2021-04-06
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018045971&_cid=P22-MGK809-27208-1
AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
References
- An R, Li YQ, Lin YL, Xu F, Li MM, Liu Z (February 2023). “EZH1/2 as targets for cancer therapy”. Cancer Gene Therapy. 30 (2): 221–235. doi:10.1038/s41417-022-00555-1. PMID 36369341.
- Wei L, Mei D, Hu S, Du S (August 2024). “Dual-target EZH2 inhibitor: latest advances in medicinal chemistry”. Future Medicinal Chemistry. 16 (15): 1561–1582. doi:10.1080/17568919.2024.2380243. PMC 11370917. PMID 39082677.
- “Epsametostat”. PatSnap.
| Clinical data | |
|---|---|
| Other names | HH2853 |
| Identifiers | |
| IUPAC name | |
| CAS Number | 2202678-06-4 |
| PubChem CID | 134340937 |
| ChemSpider | 115010245 |
| UNII | P8U5JF6NBY |
| Chemical and physical data | |
| Formula | C31H36F3N7O3 |
| Molar mass | 611.670 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
//////////Epsametostat, histone N-methyltransferase inhibitor, antineoplastic, Shanghai Haihe Pharmaceutical, HH 2853, (R)-HH2853